In order to achieve 200 per-protocol subjects, approximately 250 eligible subjects, age 18 years or older, with a history of paroxysmal or persistent NVAF who are scheduled to undergo an elective catheter ablation procedure will randomize in a 1:1 ratio to receive either rivaroxaban 20 mg orally, once-daily, preferably administered with the evening meal or uninterrupted VKA (adjusted to achieve a recommended INR of 2.0 to 3.0). Subjects not randomized to the rivaroxaban arm of the study will be initiated on, transitioned to (if not already on a VKA) or will continue to receive their usual care regimen of uninterrupted VKA.

You may be eligible for this study if you meet the following criteria:

• Conditions: Atrial Fibrillation
• Age: 1 years - 99 years
• Gender: All